Biotek-snakken — December 2025
-
Jeg ser et potentielt lignende scenarie i Pila, som stadig handles tæt på emissionskursen og til en ekstremt lav værdiansættelse (100 mio. SEK) selv om en tydelig trigger i Gubra-studiet allerede venter i januar/februar. Ofte ser man meget kraftige udbrud i denne type undervurderede forskningsselskaber efter en afsluttet kapitalrejsning og forud for afgørende milepæle.
-
Ugevideo: Zealand Pharma, Genmab, Bavarian, Nanexa & Novo https://proinvestor.com/boards/130256
-
Servicemeddelelse: Q&A med Adam Steensberg fra Zealand Pharma starter kl. 14.
-
Curasight - Nu bliver det spændende...: Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[
] in Brain Cancer https://news.cision.com/curasight/r/curasight-announces-successful-d
osing-of-first-patient-in-phase-1-trial-with-utreat--in-brain-cancer,c4284416 -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind